Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Targeted Genetics initiates phase II trials for proprietary gene therapy compound

Oct. 8, 1998

Onconase and proteasome inhibitors have synergistic antitumor activity, even in resistant tumors

Oct. 8, 1998

ADIR presents two new series of ellipticine derivatives with improved profiles

Oct. 7, 1998

Antitumor agents with high potency and selectivity under evaluation at Shionogi

Oct. 6, 1998

Inex to focus internal R&D program on three cancer drug product candidates

Oct. 6, 1998

FDA approves anthracycline with orphan drug status for carcinoma in situ of the bladder

Oct. 5, 1998

Janssen terminates Avicidin agreement with NeoRx

Oct. 2, 1998

Onyx expands ONYX-015 clinical trials in pancreatic cancer

Oct. 2, 1998

Progesterone antagonists claimed for cancer, gynecological disorders by Meiji Seika

Oct. 1, 1998

Guilford, RPR amend Gliadel marketing and distribution agreement

Oct. 1, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....